Advertisement

Molecular Medicine

, Volume 20, Issue 1, pp 569–578 | Cite as

Extracellular High-Mobility Group Box 1 Protein (HMGB1) as a Mediator of Persistent Pain

  • Nilesh M. Agalave
  • Camilla I. Svensson
Invited Review Article

Abstract

Although originally described as a highly conserved nuclear protein, high-mobility group box 1 protein (HMGB1) has emerged as a danger-associated molecular pattern molecule protein (DAMP) and is a mediator of innate and specific immune responses. HMGB1 is passively or actively released in response to infection, injury and cellular stress, providing chemotactic and cytokine-like functions in the extracellular environment, where it interacts with receptors such as receptor for advanced glycation end products (RAGE) and several Toll-like receptors (TLRs). Although HMGB1 was first revealed as a key mediator of sepsis, it also contributes to a number of other conditions and disease processes. Chronic pain arises as a direct consequence of injury, inflammation or diseases affecting the somatosensory system and can be devastating for the affected patients. Emerging data indicate that HMGB1 is also involved in the pathology of persistent pain. Here, we give an overview of HMGB1 as a proinflammatory mediator, focusing particularly on the role of HMGB1 in the induction and maintenance of hypersensitivity in experimental models of pain and discuss the therapeutic potential of targeting HMGB1 in conditions of chronic pain.

References

  1. 1.
    Ueda T, Yoshida M. (2010) HMGB proteins and transcriptional regulation. Biochim. Biophys. Acta. 1799:114–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Andersson U, Tracey KJ. (2011) HMGB1 is a therapeutic target for sterile inflammation and infection. Annu. Rev. Immunol. 29:139–62.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Harris HE, Andersson U, Pisetsky DS. (2012) HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat. Rev. Rheumatol. 8:195–202.CrossRefGoogle Scholar
  4. 4.
    Park JS, et al. (2004) Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem. 279:7370–7.CrossRefGoogle Scholar
  5. 5.
    van Beijnum JR, Buurman WA, Griffioen AW. (2008) Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis. 11:91–9.CrossRefGoogle Scholar
  6. 6.
    Wang H, et al. (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science. 285:248–51.CrossRefGoogle Scholar
  7. 7.
    Maeda T, Ozaki M, Kobayashi Y, Kiguchi N, Kishioka S. (2013) HMGB1 as a potential therapeutic target for neuropathic pain. J. Pharmacol. Sci. 123:301–5.CrossRefPubMedGoogle Scholar
  8. 8.
    Woolf CJ, Salter MW. (2000) Neuronal plasticity: increasing the gain in pain. Science. 288:1765–9.CrossRefGoogle Scholar
  9. 9.
    Zeilhofer HU. (2005) Synaptic modulation in pain pathways. Rev. Physiol. Biochem. Pharmacol. 154:73–100.PubMedGoogle Scholar
  10. 10.
    Xu Q, Yaksh TL. (2011) A brief comparison of the pathophysiology of inflammatory versus neuropathic pain. Curr. Opin. Anaesthesiol. 24:400–7.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Costigan M, Scholz J, Woolf CJ. (2009) Neuropathic pain: a maladaptive response of the nervous system to damage. Annu. Rev. Neurosci. 32:1–32.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Gangadharan V, Kuner R. (2013) Pain hypersensitivity mechanisms at a glance. Dis. Model Mech. 6:889–95.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    McMahon SB, Malcangio M. (2009) Current challenges in glia-pain biology. Neuron. 64:46–54.CrossRefPubMedGoogle Scholar
  14. 14.
    Basbaum AI, Bautista DM, Scherrer G, Julius D. (2009) Cellular and molecular mechanisms of pain. Cell. 139:267–84.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Woolf CJ. (2010) What is this thing called pain? J. Clin. Invest. 120:3742–4.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Latremoliere A, Woolf CJ. (2009) Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J. Pain. 10:895–926.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Dublin P, Hanani M. (2007) Satellite glial cells in sensory ganglia: their possible contribution to inflammatory pain. Brain Behav. Immun. 21:592–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Zhang H, et al. (2009) Altered functional properties of satellite glial cells in compressed spinal ganglia. Glia. 57:1588–99.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Takeda M, et al. (2007) Enhanced excitability of nociceptive trigeminal ganglion neurons by satellite glial cytokine following peripheral inflammation. Pain. 129:155–66.CrossRefPubMedGoogle Scholar
  20. 20.
    Svensson CI, Brodin E. (2010) Spinal astrocytes in pain processing: non-neuronal cells as therapeutic targets. Mol. Interv. 10:25–38.CrossRefPubMedGoogle Scholar
  21. 21.
    Ji RR, Berta T, Nedergaard M. (2013) Glia and pain: is chronic pain a gliopathy? Pain. 154 Suppl 1: S10–28.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Grace PM, Hutchinson MR, Maier SF, Watkins LR. (2014) Pathological pain and the neuroimmune interface. Nat. Rev. Immunol. 14:217–31.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Tsung A, et al. (2007) HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. J. Exp. Med. 204:2913–23.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Scaffidi P, Misteli T, Bianchi ME. (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 418:191–5.CrossRefGoogle Scholar
  25. 25.
    Gardella S, et al. (2002) The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep. 3:995–1001.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Kang R, et al. (2014) HMGB1 in health and disease. Mol. Aspects Med. 40C:1–116.Google Scholar
  27. 27.
    Jiang W, Pisetsky DS. (2006) The role of IFN-alpha and nitric oxide in the release of HMGB1 by RAW 264.7 cells stimulated with polyinosinicpolycytidylic acid or lipopolysaccharide. J. Immunol. 177:3337–43.CrossRefPubMedGoogle Scholar
  28. 28.
    Lu B, et al. (2014) JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation. Proc. Natl. Acad. Sci. U. S. A. 111:3068–73.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Rendon-Mitchell B, et al. (2003) IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J. Immunol. 170:3890–7.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Zhou JR, et al. (2013) Neuropeptide Y induces secretion of high-mobility group box 1 protein in mouse macrophage via PKC/ERK dependent pathway. J. Neuroimmunol. 260:55–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Bonaldi T, et al. (2003) Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 22:5551–60.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Ito I, Fukazawa J, Yoshida M. (2007) Post-translational methylation of high mobility group box 1 (HMGB1) causes its cytoplasmic localization in neutrophils. J. Biol. Chem. 282:16336–44.CrossRefPubMedGoogle Scholar
  33. 33.
    Zhang X, et al. (2008) Calcium/calmodulin-dependent protein kinase (CaMK) IV mediates nucleocytoplasmic shuttling and release of HMGB1 during lipopolysaccharide stimulation of macrophages. J. Immunol. 181:5015–23.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Ma L, Kim SJ, Oh KI. (2012) Calcium/calmodulin-dependent protein kinase is involved in the release of high mobility group box 1 via the interferonbeta signaling pathway. Immune Netw. 12:148–54.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Oh YJ, et al. (2009) HMGB1 is phosphorylated by classical protein kinase C and is secreted by a calcium-dependent mechanism. J. Immunol. 182:5800–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Lu B, et al. (2012) Novel role of PKR in inflammasome activation and HMGB1 release. Nature. 488:670–4.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Feldman P, Due MR, Ripsch MS, Khanna R, White FA. (2012) The persistent release of HMGB1 contributes to tactile hyperalgesia in a rodent model of neuropathic pain. J. Neuroinflammation. 9:180.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Allette YM, et al. (2014) Identification of a functional interaction of HMGB1 with receptor for advanced glycation end-products in a model of neuropathic pain. Brain Behav. Immun. 42:169–77.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Pedrazzi M, et al. (2012) Potentiation of NMDA receptor-dependent cell responses by extracellular high mobility group box 1 protein. PLoS One. 7:e44518.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Balosso S, Liu J, Bianchi ME, Vezzani A. (2014) Disulfide-containing high mobility group box-1 promotes N-methyl-D-aspartate receptor function and excitotoxicity by activating Toll-like receptor 4-dependent signaling in hippocampal neurons. Antioxid. Redox. Signal. 21:1726–40.CrossRefPubMedGoogle Scholar
  41. 41.
    Chiavegato A, Zurolo E, Losi G, Aronica E, Carmignoto G. (2014) The inflammatory molecules IL-1β and HMGB1 can rapidly enhance focal seizure generation in a brain slice model of temporal lobe epilepsy. Front. Cell. Neurosci. 8:155.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Hori O, et al. (1995) The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin: mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem. 270:25752–61.CrossRefGoogle Scholar
  43. 43.
    Ivanov S, et al. (2007) A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood. 110:1970–81.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Chen GY, Tang J, Zheng P, Liu Y. (2009) CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science. 323:1722–5.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Orlova VV, et al. (2007) A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J. 26:1129–39.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Sha Y, Zmijewski J, Xu Z, Abraham E. (2008) HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J. Immunol. 180:2531–7.CrossRefGoogle Scholar
  47. 47.
    Campana L, Bosurgi L, Bianchi ME, Manfredi AA, Rovere-Querini P. (2009) Requirement of HMGB1 for stromal cell-derived factor-1/CXCL12-dependent migration of macrophages and dendritic cells. J. Leukoc. Biol. 86:609–15.CrossRefPubMedGoogle Scholar
  48. 48.
    Hreggvidsdottir HS, et al. (2012) High mobility group box protein 1 (HMGB1)-partner molecule complexes enhance cytokine production by signaling through the partner molecule receptor. Mol. Med. 18:224–30.CrossRefPubMedGoogle Scholar
  49. 49.
    Venereau E, et al. (2012) Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J. Exp. Med. 209:1519–28.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Yang H, et al. (2012) Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol. Med. 18:250–9.CrossRefGoogle Scholar
  51. 51.
    Huttunen HJ, Fages C, Kuja-Panula J, Ridley AJ, Rauvala H. (2002) Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res. 62:4805–11.Google Scholar
  52. 52.
    McMahon SB, Cafferty WB, Marchand F. (2005) Immune and glial cell factors as pain mediators and modulators. Exp. Neurol. 192:444–62.CrossRefPubMedGoogle Scholar
  53. 53.
    Wadachi R, Hargreaves KM. (2006) Trigeminal nociceptors express TLR-4 and CD14: a mechanism for pain due to infection. J. Dent. Res. 85:49–53.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Li Y, et al. (2014) Toll-like receptor 4 signaling contributes to Paclitaxel-induced peripheral neuropathy. J. Pain. 15:712–25.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Due MR, et al. (2012) Neuroexcitatory effects of morphine-3-glucuronide are dependent on Toll-like receptor 4 signaling. J. Neuroinflammation. 9:200.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Shibasaki M, et al. (2010) Induction of high mobility group box-1 in dorsal root ganglion contributes to pain hypersensitivity after peripheral nerve injury. Pain. 149:514–21.CrossRefPubMedGoogle Scholar
  57. 57.
    Nicotra L, Loram LC, Watkins LR, Hutchinson MR. (2012) Toll-like receptors in chronic pain. Exp. Neurol. 234:316–29.CrossRefPubMedGoogle Scholar
  58. 58.
    Chacur M, et al. (2001) A new model of sciatic inflammatory neuritis (SIN): induction of unilateral and bilateral mechanical allodynia following acute unilateral peri-sciatic immune activation in rats. Pain. 94:231–44.CrossRefPubMedGoogle Scholar
  59. 59.
    Tanaka J, et al. (2013) Recombinant human soluble thrombomodulin prevents peripheral HMGB1-dependent hyperalgesia in rats. Br. J. Pharmacol. 170:1233–41.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Milligan ED, et al. (2003) Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. J. Neurosci. 23:1026–40.CrossRefPubMedGoogle Scholar
  61. 61.
    Tanaka J, et al. (2014) Bladder pain relief by HMGB1 neutralization and soluble thrombomodulin in mice with cyclophosphamide-induced cystitis. Neuropharmacology. 79:112–8.CrossRefPubMedGoogle Scholar
  62. 62.
    Kokkola R, et al. (2002) High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis. Arthritis Rheum. 46:2598–603.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Pullerits R, et al. (2003) High mobility group box chromosomal protein 1, a DNA binding cytokine, induces arthritis. Arthritis Rheum. 48:1693–700.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    O’Connor KA, et al. (2003) Further characterization of high mobility group box 1 (HMGB1) as a proinflammatory cytokine: central nervous system effects. Cytokine. 24:254–65.CrossRefPubMedGoogle Scholar
  65. 65.
    Agalave NM, et al. (2014) Spinal HMGB1 induces TLR4-mediated long-lasting hypersensitivity and glial activation and regulates pain-like behavior in experimental arthritis. Pain. 155:1802–13.CrossRefGoogle Scholar
  66. 66.
    Hoppe G, Talcott KE, Bhattacharya SK, Crabb JW, Sears JE. (2006) Molecular basis for the redox control of nuclear transport of the structural chromatin protein Hmgb1. Exp. Cell. Res. 312:3526–38.CrossRefPubMedGoogle Scholar
  67. 67.
    Calogero S, et al. (1999) The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat. Genet. 22:276–80.CrossRefGoogle Scholar
  68. 68.
    Kang R, et al. (2014) Intracellular Hmgb1 inhibits inflammatory nucleosome release and limits acute pancreatitis in mice. Gastroenterology. 146:1097–107.CrossRefGoogle Scholar
  69. 69.
    Yanai H, et al. (2013) Conditional ablation of HMGB1 in mice reveals its protective function against endotoxemia and bacterial infection. Proc. Natl. Acad. Sci. U. S. A. 110:20699–704.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Kokkola R, et al. (2003) Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum. 48:2052–8.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Andersson U, Erlandsson-Harris H, Yang H, Tracey KJ. (2002) HMGB1 as a DNA-binding cytokine. J. Leukoc. Biol. 72:1084–91.Google Scholar
  72. 72.
    Yang H, et al. (2004) Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl. Acad. Sci. U. S. A. 101:296–301.CrossRefGoogle Scholar
  73. 73.
    Mollica L, et al. (2007) Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem. Biol. 14:431–41.CrossRefGoogle Scholar
  74. 74.
    Abeyama K, et al. (2005) The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J. Clin. Invest. 115:1267–74.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Nakamura Y, et al. (2013) Neuropathic pain in rats with a partial sciatic nerve ligation is alleviated by intravenous injection of monoclonal antibody to high mobility group box-1. PLoS One. 8:e73640.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Otoshi K, Kikuchi S, Kato K, Sekiguchi M, Konno S. (2011) Anti-HMGB1 neutralization antibody improves pain-related behavior induced by application of autologous nucleus pulposus onto nerve roots in rats. Spine (Phila Pa 1976). 36:E692–8.CrossRefGoogle Scholar
  77. 77.
    Wahamaa H, et al. (2011) High mobility group box protein 1 in complex with lipopolysaccharide or IL-1 promotes an increased inflammatory phenotype in synovial fibroblasts. Arthritis Res. Ther. 13:R136.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Hreggvidsdottir HS, et al. (2009) The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J. Leukoc. Biol. 86:655–62.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Tong W, et al. (2010) Spinal high-mobility group box 1 contributes to mechanical allodynia in a rat model of bone cancer pain. Biochem. Biophys. Res. Commun. 395:572–6.CrossRefPubMedGoogle Scholar
  80. 80.
    Ren PC, et al. (2012) High-mobility group box 1 contributes to mechanical allodynia and spinal astrocytic activation in a mouse model of type 2 diabetes. Brain Res. Bull. 88:332–7.CrossRefPubMedGoogle Scholar
  81. 81.
    Bas DB, et al. (2012) Collagen antibody-induced arthritis evokes persistent pain with spinal glial involvement and transient prostaglandin dependency. Arthritis Rheum. 64:3886–96.CrossRefPubMedGoogle Scholar
  82. 82.
    Su J, et al. (2015) Phenotypic changes in dorsal root ganglion and spinal cord in the collagen antibody-induced arthritis mouse model. J. Comp. Neurol. 2015, Jan 29 [Epub ahead of print].Google Scholar
  83. 83.
    Kim ID, Lee JK. (2013) HMGB1-binding heptamer confers anti-inflammatory effects in primary microglia culture. Exp. Neurobiol. 22:301–7.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Kim SW, et al. (2012) Glycyrrhizic acid affords robust neuroprotection in the postischemic brain via anti-inflammatory effect by inhibiting HMGB1 phosphorylation and secretion. Neurobiol. Dis. 46:147–56.CrossRefPubMedGoogle Scholar
  85. 85.
    Shin JH, Lee HK, Lee HB, Jin Y, Lee JK. (2014) Ethyl pyruvate inhibits HMGB1 phosphorylation and secretion in activated microglia and in the postischemic brain. Neurosci. Lett. 558:159–63.CrossRefPubMedGoogle Scholar
  86. 86.
    Zurolo E, et al. (2011) Activation of Toll-like receptor, RAGE and HMGB1 signalling in malformations of cortical development. Brain. 134:1015–32.CrossRefPubMedGoogle Scholar
  87. 87.
    Kim JB, et al. (2006) HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. J. Neurosci. 26:6413–21.CrossRefPubMedGoogle Scholar
  88. 88.
    Laird MD, et al. (2014) High mobility group box protein-1 promotes cerebral edema after traumatic brain injury via activation of toll-like receptor 4. Glia. 62:26–38.CrossRefPubMedGoogle Scholar
  89. 89.
    Pedrazzi M, et al. (2007) Selective proinflammatory activation of astrocytes by high-mobility group box 1 protein signaling. J. Immunol. 179:8525–32.CrossRefPubMedGoogle Scholar
  90. 90.
    Qiu J, et al. (2010) High-mobility group box 1 promotes metalloproteinase-9 upregulation through Toll-like receptor 4 after cerebral ischemia. Stroke. 41:2077–82.CrossRefPubMedPubMedCentralGoogle Scholar
  91. 91.
    Bonanno G, et al. (2007) The high-mobility group box 1 cytokine induces transporter-mediated release of glutamate from glial subcellular particles (gliosomes) prepared from in situ-matured astrocytes. Int. Rev. Neurobiol. 82:73–93.CrossRefPubMedGoogle Scholar
  92. 92.
    Antoine DJ, et al. (2009) High-mobility group box-1 protein and keratin-18, circulating serum proteins informative of acetaminophen-induced necrosis and apoptosis in vivo. Toxicol. Sci. 112:521–31.CrossRefPubMedPubMedCentralGoogle Scholar
  93. 93.
    Zetterstrom CK, et al. (2008) Pivotal advance: inhibition of HMGB1 nuclear translocation as a mechanism for the anti-rheumatic effects of gold sodium thiomalate. J. Leukoc. Biol. 83:31–8.CrossRefPubMedGoogle Scholar
  94. 94.
    Tsai CY, et al. (2012) Size-dependent attenuation of TLR9 signaling by gold nanoparticles in macrophages. J. Immunol. 188:68–76.CrossRefPubMedGoogle Scholar
  95. 95.
    Ostberg T, et al. (2008) Oxaliplatin retains HMGB1 intranuclearly and ameliorates collagen type II-induced arthritis. Arthritis Res. Ther. 10:R1.CrossRefPubMedPubMedCentralGoogle Scholar
  96. 96.
    Ling B, Authier N, Balayssac D, Eschalier A, Coudore F. (2007) Behavioral and pharmacological description of oxaliplatin-induced painful neuropathy in rat. Pain. 128:225–34.CrossRefPubMedGoogle Scholar
  97. 97.
    Ling B, et al. (2007) Behavioral and immunohistological assessment of painful neuropathy induced by a single oxaliplatin injection in the rat. Toxicology. 234:176–84.CrossRefPubMedGoogle Scholar
  98. 98.
    Melemedjian OK, et al. (2011) Targeting adenosine monophosphate-activated protein kinase (AMPK) in preclinical models reveals a potential mechanism for the treatment of neuropathic pain. Mol. Pain. 7:70.CrossRefPubMedPubMedCentralGoogle Scholar
  99. 99.
    He Z, Guo Q, Xiao M, He C, Zou W. (2013) Intrathecal lentivirus-mediated transfer of interleukin-10 attenuates chronic constriction injury-induced neuropathic pain through modulation of spinal high-mobility group box 1 in rats. Pain Physician. 16:E615–25.PubMedGoogle Scholar
  100. 100.
    Kuang X, et al. (2012) Effects of intrathecal epigallocatechin gallate, an inhibitor of Toll-like receptor 4, on chronic neuropathic pain in rats. Eur. J. Pharmacol. 676:51–6.CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2014

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (https://doi.org/creativecommons.org/licenses/by-nc-nd/4.0/)

Authors and Affiliations

  1. 1.Department of Physiology and PharmacologyKarolinska InstitutetStockholmSweden

Personalised recommendations